参考文献 References
[1] 刘刚. 探讨美托洛尔联合非洛地平治疗社区高血压的临床疗效[J]. 中国社区医师,2021,37(30):60-61.
[2] 邵皎巍. 美托洛尔同非洛地平治疗社区高血压对血压水平的影响[J]. 北方药学,2021,18(07):143-144.
[3] 惠宇平,乔蕾,张荣荣,田能. 美托洛尔联合非洛地平治疗社区高血压临床效果与安全性分析[J]. 中国药物与临床,2021,21(07):1145-1146.
[4] 朱笑天,王艳哲,张秀云. 非洛地平联合美托洛尔对高血压患者血压与糖脂代谢指标的影响[J]. 现代医学与健康研究电子杂志,2021,5(03):135-137.
[5] 郭小婷,徐华,韩晓红. 非洛地平缓释片联合美托洛尔治疗原发性高血压合并心力衰竭的效果观察[J]. 中国实用医刊,2020,47(21):98-101.
[6] 吕红霞. 非洛地平联合美托洛尔在基层医院高血压患者治疗中的应用效果[J]. 中西医结合心血管病电子杂志,2020,8(22):41.
[7] 柴飞. 美托洛尔联合非洛地平治疗社区高血压患者的临床疗效[J]. 中国社区医师,2020,36(19):12-13.
[8] 王月春. 美托洛尔、非洛地平联合治疗社区高血压的临床有效性、安全性分析[J]. 临床医药文献电子杂志,2020,7(43):144+166.
[9] 苏振美,张晓红,李花,陆志雄,冯雪峰. 观察美托洛尔联合非洛地平治疗社区高血压的临床疗效[J]. 中国社区医师,2020,36(12):74+76.
[10] 孙建花,陈羽嫣,薄其凤. 美托洛尔联合非洛地平治疗社区高血压的有效性及安全性研究[J]. 中国社区医师,2020,36(08):60+62.
[11] Zhong Qi,Wu Hua-bing,Niu Qin-shan,Jia Ping-ping,Qin Qi-rong,Wang Xiao-dong,He Jia-liu,Yang Wan-jun,Huang Fen. Exposure to multiple metals and the risk of hypertension in adults: A prospective cohort study in a local area on the Yangtze River, China[J]. Environment International,2021,153.
[12] Deng Yue,Li Shuangyue,Chen Zhenzhen,Wang Wenjie, Geng Bin,Cai Jun. Mdivi-1, a mitochondrial fission inhibitor, reduces angiotensin-II- induced hypertension by mediating VSMC phenotypic switch[J]. Biomedicine & Pharmacotherapy,2021,140.
[13] Gu Yeqing,Dong Jun,Meng Ge,Zhang Qing,Liu Li,Wu Hongmei, Zhang Shunming,Wang Yawen,Zhang Tingjing, Wang Xuena,Sun Shaomei,Wang Xing,Jia Qiyu,Song Kun,Liu Qiang,Niu Kaijun. Handgrip strength as a predictor of incident hypertension in the middle-aged and older population: The TCLSIH cohort study[J]. Maturitas, 2021,150.
[14] Madika Anne-Laure,MacDonald Conor James,Gelot Amandine, Hitier Sixtine,Mounier-Vehier Claire,Béraud Guillaume, Kvaskoff Marina,Boutron-Ruault Marie- Christine, Bonnet Fabrice. Hysterectomy, non-malignant gynecological diseases, and the risk of incident hypertension: The E3N prospective cohort[J]. Maturitas, 2021,15